SpaceX launches rescue for NASA astronauts stuck in space until 2025

Peoples Financial Services (NASDAQ:PFIS), a Pennsylvania community bank holding company, reported Q2 2025 earnings of $1.68 per share, exceeding the $1.47 forecast and significantly up from $0.46 a year prior. The bank saw net interest income more than double year-over-year, reflecting successful merger integration and improved efficiency ratios and asset quality. Want More Context? 🔎

Sirius XM (NASDAQ:SIRI) reported Q2 2025 earnings on July 31, revealing GAAP earnings per share of $0.57, missing expectations by $0.20 due to decreased net income and higher legal and restructuring costs. Despite showcasing strong free cash flow and innovation in content, profitability pressures persist; management remains optimistic about the full-year outlook amid challenging subscriber trends. Want More Context? 🔎

XRP (CRYPTO: XRP) experienced a notable 43% gain over 30 days ending July 29, but seasoned investors anticipate a pullback is inevitable, questioning its timing and depth. Key factors may soon trigger this correction, though past dips in XRP often appear as opportunities rather than failures, suggesting underlying strength in its long-term investment thesis. Want More Context? 🔎

Seacor Marine (NYSE:SMHI) reported Q2 2025 results on July 30, revealing GAAP revenue of $60.8 million, missing expectations by 12.3%, while its GAAP loss per share of $(0.26) was slightly better than anticipated. The company's operating revenue declined by 13.0% year-over-year due to high repair expenses, although ongoing fleet modernization efforts showed some sequential improvements. Want More Context? 🔎

Shares of Micron Technology (NASDAQ: MU) fell 5.2% on Thursday morning, primarily due to issues attributed to Samsung, rather than any specific actions by Micron itself. The decline highlights the interconnected nature of the semiconductor industry and how external factors can significantly impact stock performance. Want More Context? 🔎

Lenz Therapeutics (NASDAQ:LENZ) reported second quarter 2025 results on July 30, revealing $5.0 million in GAAP revenue from licensing milestones, significantly surpassing analyst expectations. Despite a deeper net loss due to increased spending, the company made strides in its commercial plans ahead of an important FDA decision for its lead product, LNZ100, aimed at treating presbyopia. Want More Context? 🔎